LIG4抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09958(LIG4 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The LIG4 antibody targets DNA ligase IV (LIG4), a critical enzyme in the non-homologous end joining (NHEJ) pathway, which repairs DNA double-strand breaks (DSBs) in mammalian cells. LIG4 forms a complex with XRCC4 and XLF to catalyze the final ligation step during NHEJ, ensuring genomic stability. Mutations in the *LIG4* gene are linked to rare disorders like LIG4 syndrome, characterized by developmental abnormalities, immunodeficiency, and increased cancer susceptibility. Research on LIG4 also connects it to V(D)J recombination, a process essential for immune diversity.

Antibodies against LIG4 are vital tools in studying DNA repair mechanisms, cellular responses to radiation or chemotherapeutic agents, and diseases involving genomic instability. They are employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect LIG4 expression levels, localization, and interactions. Commercial LIG4 antibodies are typically developed using recombinant protein fragments or peptide antigens, validated for specificity in knockout cell lines or tissues.

Dysregulation of LIG4 is implicated in cancer progression and treatment resistance, making its detection relevant for both basic research and clinical diagnostics. Studies also explore LIG4's role in aging and neurodegenerative disorders. However, challenges remain in standardizing antibody performance across experimental conditions. Continued development of high-affinity, well-validated LIG4 antibodies supports advances in understanding DNA repair biology and therapeutic targeting.